MRUS
Merus N.V
Halal Rating :
Last Price
$39.55
Last updated:
Market Cap
-
7D Change
-2.22%
1 Year Change
13.39%
Company Overview
Industries
Exchange
Next Earnings Date
Merus N.V. is a clinical-stage oncology company developing innovative antibody therapeutics. The company focuses on developing multispecific antibody candidates, particularly bispecific and trispecific antibodies, for the treatment of various types of cancer. Their proprietary technology platform, Biclonics®, allows them to generate full-length human bispecific antibody therapeutics.
Use of Interest
| Reporting Date | Total Revenue | Total Operating Expense | Interest Income | Interest Expense | Interest Income Ratio | Interest Expense Ratio |
|---|---|---|---|---|---|---|
| Sept. 30, 2024 | $11.77m | $73.75m | - | $-10254000.0 | 0.00% | 13.90% |
| June 30, 2024 | $7.33m | $64.58m | - | $-7130000.0 | 0.00% | 11.04% |
| March 31, 2024 | $7.89m | $49.78m | - | $-4917000.0 | 0.00% | 9.88% |
Company Impact
Help us evaluate Merus N.V's impact from a halal perspective. Vote on the most significant aspect and submit any considerations that we may have missed.